Immunocore Could Gain Green Light For First T-Cell Receptor Drug In Early 2022
Tebentafusp Granted Rare EU Accelerated Assessment
The UK biotech is the first company to file a T-cell receptor therapy with regulators, a class with potential to hit targets unreachable for antibodies and CAR-Ts.
You may also be interested in...
Deal Watch: J&J Partners On Bispecific Antibody R&D With F-Star, Xencor
Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.
Leucid Bio Unveils ‘Parallel CAR-T’ Platform Targeting Solid Tumors
The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.
Keeping Track: New Formulations Dominate In CNS; Immunocore Brings First TCR Therapy To US FDA
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.